Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 4, 2012, Pages

  Matsuo, Yukinori ^a   Shibuya, Keiko ^a   Nakamura, Mitsuhiro ^a   Narabayashi, Masaru ^a   Sakanaka, Katsuyuki ^a   Ueki, Nami ^a   Miyagi, Ken ^a   Norihisa, Yoshiki ^a   Mizowaki, Takashi ^a   Nagata, Yasushi ^b   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Dose volume analysis; Radiation pneumonitis; Stereotactic body radiation therapy

Indexed keywords

ADVERSE EVENTS; COMMON TERMINOLOGY CRITERIA; DOSE-VOLUME; DOSE-VOLUME ANALYSIS; HIGHLY-CORRELATED; ISOCENTERS; LUNG CANCER; MEAN LUNG DOSE; PATIENT POPULATION; RADIATION PNEUMONITIS; STEREOTACTIC BODY RADIATION THERAPY;

BIOLOGICAL ORGANS; DISEASES; OPTIMIZATION;

RADIOTHERAPY;

STEROID;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENT; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; REFERENCE VALUE; STEREOTACTIC BODY RADIATION THERAPY; STEROID THERAPY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION PNEUMONITIS; RADIOSURGERY; RADIOTHERAPY DOSAGE; TUMOR BURDEN;

EID: 84862699705     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.01.018     Document Type: Article

References (20)

1. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076.
2. Nagata Y, Hiraoka M, Shibata T, et al. A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403). Int J Radiat Oncol Biol Phys 2010;78:S27-S28.
3. Palma D, Visser O, Lagerwaard FJ, et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I nonsmall- cell lung cancer: A population-based time-trend analysis. J Clin Oncol 2010;28:5153-5159.
4. Baumann P, Nyman J, Hoyer M, et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol 2008;88:359-367.
5. Yamashita H, Nakagawa K, Nakamura N, et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2007;2:21.
6. Ricardi U, Filippi AR, Guarneri A, et al. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy. Acta Oncol 2009;48:571-577.
7. Borst GR, Ishikawa M, Nijkamp J, et al. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol 2009;91:307-313.
8. Guckenberger M, Baier K, Polat B, et al. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol 2010;97:65-70.
9. Ong CL, Palma D, Verbakel WFAR, Slotman BJ, Senan S. Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): Planning considerations and early toxicity. Radiother Oncol 2010;97:431-436.
10. Barriger RB, Forquer JA, Brabham JG, et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2012;82:457-462.
11. Stauder MC, Macdonald OK, Olivier KR, et al. Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. Radiother Oncol 2011;99:166-171.
12. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010;76:S70-S76.
13. Takayama K, Nagata Y, Negoro Y, et al. Treatment planning of stereotactic radiotherapy for solitary lung tumor. Int J Radiat Oncol Biol Phys 2005;61:1565-1571.
14. Hiraoka M, Matsuo Y, Takayama K. Stereotactic body radiation therapy for lung cancer: Achievements and perspectives. Jpn J Clin Oncol 2010;40:846-854.
15. Tucker SL, Jin H, Wei X, et al. Impact of toxicity grade and scoring system on the relationship between mean lung dose and risk of radiation pneumonitis in a large cohort of patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2010;77:691-698.
16. De Jaeger K, Hoogeman MS, Engelsman M, et al. Incorporating an improved dose-calculation algorithm in conformal radiotherapy of lung cancer: Re-evaluation of dose in normal lung tissue. Radiother Oncol 2003;69:1-10.
17. Hara R, Itami J, Komiyama T, Katoh D, Kondo T. Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. Chest 2004;125:340-344.
18. Iwata H, Shibamoto Y, Baba F, et al. Correlation between the serum KL-6 level and the grade of radiation pneumonitis after stereotactic body radiotherapy for stage I lung cancer or small lung metastasis. Radiother Oncol 2011;101:267-270.
19. Yamashita H, Kobayashi-Shibata S, Terahara A, et al. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol 2010;5:32.
20. Takeda A, Ohashi T, Kunieda E, et al. Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors. Int J Radiat Oncol Biol Phys 2010;77:685-690.